The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Construction
  • Technology
  • Health
  • Entertainment
  • Marketing

Coeptis Therapeutics Announces Reverse Stock Split
The PennZone/10291361

Trending...
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
WEXFORD, Pa., Dec. 27, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has announced its plans to proceed with a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. The decision was made following authorization by the company's board of directors and majority stockholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40.

The reverse stock split, also known as a consolidation, will see every 20 shares of the company's outstanding and issued common stock converted into one share. This move is intended to help Coeptis meet the minimum bid price requirement necessary to maintain its listing on the Nasdaq Capital Market. Under Nasdaq rules, listed companies must maintain a minimum bid price of at least $1.00 per share.

The decision to proceed with the reverse split was approved by Coeptis' stockholders at the company's Annual Stockholder's Meeting on December 18, 2024. Following this meeting, the Board established the reverse split ratio and authorized it to proceed.

More on The PennZone
  • New Thriller 'Counterframe' Explores the Hidden Vulnerabilities of Modern Society
  • Award-Winning Heritage at South Brunswick Continues to Thrive as One of New Jersey's Premier New Home Communities
  • Four Seasons Cleaners Debuts Santa Barbara County's First 24/7 Dry Cleaning Kiosk New self-service
  • WhereTu Launches to Help Americans Build Successful Lives Abroad
  • Alcom Printing Achieves SGP Recertification

The first day of trading on a post-split basis on the Nasdaq Capital Market will be at market open on December 31, 2024. Upon the effective date of the Reverse Split, any fractional shares for record holders that would have resulted from the split will be rounded up to the next whole number. This will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

Continental Stock Transfer has been appointed as the exchange agent and transfer agent for the reverse stock split. They will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new ones if they wish to do so. However, those who hold their shares in brokerage accounts or "street name" are not required to take any action.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. The company's product portfolio includes assets licensed from Deverra Therapeutics and the University of Pittsburgh. It is also developing a universal CAR technology in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute.

More on The PennZone
  • John Marc Rittle Receives Pennsylvania's Most Influential Leaders Award
  • Appliance EMT Expands Built-In and Walk-In Refrigerator Service in Metro Atlanta
  • LawProactive Launches SB 37-Compliant Attorney Marketing Software With Exclusive City Territories Across California
  • Cogs and Marvel expands EMEA leadership team for next phase of growth
  • Beat the Philly Heat: Mid-July AC Boost

The Company's CEO expressed excitement about the potential of their innovative cell therapy platforms to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis is headquartered in Wexford, PA.

Investors are advised to exercise caution when considering any investment in Coeptis Therapeutics Holdings, Inc. as there are inherent risks associated with investing in biopharmaceutical companies. For more information on Coeptis and its developments, visit https://coeptistx.com.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • J. Kenton Pierce Wins Prometheus Award for Best Novel
  • Ezra Wohlgelernter Named as a 2026 Philadelphia Power Broker by City & State PA
  • Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
  • Brett Furman Launches Ranks Grow
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Sounds of LA County: 27 Parks.108 Concerts. One County
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • Blueshirt Media Joins the Dazos Partner Program, Expanding HIPAA-Compliant AI Admissions Support for Behavioral Health Organizations
  • Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • World Cup Crowds Are a Stress Test for America's Restrooms
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
  • Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene
  • Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
  • Imagen Golf Announces Strategic Partnership with The Back Nine of Yardley to Deliver World-Class Indoor Golf Instruction
  • Jazzin' On Ridge Returns for Its 6th Annual Celebration of Music, Culture, and Community

Popular on PennZone

  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
  • Top 5 Most Reliable Used Vans in the UK in 2026
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Turnstone Creative's Ashley Russo Serves as Emcee for United Way's 2026 NERC and Women's Summit
  • Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
  • Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
  • Together We Thrive: Kingdom Life Health & Career Fair Unites Faith, Wellness and Opportunity
  • Custom Woodworker Launches Updated Website
  • Compton to host first Juneteenth celebration with We Are Us Festival

Similar on PennZone

  • Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
  • Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)
  • Alcom Printing Achieves SGP Recertification
  • Appliance EMT Expands Built-In and Walk-In Refrigerator Service in Metro Atlanta
  • Cogs and Marvel expands EMEA leadership team for next phase of growth
  • T. Jones Group Celebrates Two Wins and Multiple Project Nominations at the 2026 HAVAN Awards
  • Search Is Broken. Curated Discovery Is the Future
  • Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us